StreetAlpha.app
Home › Stocks › TMCI

Treace Medical Concepts, Inc. (TMCI)

$4.31
▼ −0.92%
LAST CLOSE · NOV 20

Treace Medical Concepts makes surgical systems and implants for correcting bunions and related midfoot deformities. It last closed at $4.31 on Nov 20, down 0.92% on the day. The next earnings report for TMCI is expected around Tue, Jan 12, 2027. For the quarter ended Sep 2026, TMCI reported EPS of -$0.19 on revenue of $48.3M, with revenue down 3.9% from a year ago. Over its last 8 reports the stock moved an average of 10.3% the session after earnings. Over the last 12 months TMCI insiders bought $1.4M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is TMCI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TMCI.

Key Stats

Last 12 months
Results
Revenue
$203.3M
−7.1% vs a year ago
Net income
−$55.8M
−27.4% margin
EPS (diluted)
−$0.85
Free cash flow
−$18.6M
−9.1% margin
Valuation
Market cap
$282.6M
65.6M shares
P/E
–
No P/E while losing money
Price to sales
1.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$7.8M
At Sep 30
Debt
$56.3M
At Sep 30
Shareholder equity
$61.6M
Shares outstanding
65.6M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $94.4M$94.4MFY2021FY2022: $141.8M$141.8MFY2022FY2023: $187.1M$187.1MFY2023FY2024: $209.4M$209.4MFY2024FY2025: $212.7M$212.7MFY2025

From TMCI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Jan 12
Estimated date · Time not announced
Reported EPS
-$0.19
Quarter ended Sep 2026
Year ago EPS
-$0.26
Same quarter last year
Revenue
$48.3M
−3.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.01Dec '24Mar 2025: -$0.25Mar '25Jun 2025: -$0.28Jun '25Sep 2025: -$0.26Sep '25Dec 2025: -$0.14Dec '25Mar 2026: -$0.28Mar '26Jun 2026: -$0.24Jun '26Sep 2026: -$0.19Sep '26Latest -$0.19
Revenue by quarter
Dec 2024: $68.7MDec '24Mar 2025: $52.6MMar '25Jun 2025: $47.4MJun '25Sep 2025: $50.2MSep '25Dec 2025: $62.5MDec '25Mar 2026: $47.2MMar '26Jun 2026: $45.4MJun '26Sep 2026: $48.3MSep '26Latest $48.3M
How TMCI moved after its last 8 reports
Average move the session after a report ±10.3%
Nov 6, 2026Time not announced−3.6%
Aug 7, 2026Time not announced+8.7%
Apr 9, 2026Time not announced+9.3%
Feb 27, 2026Time not announced−11.4%
Jan 13, 2026Time not announced−3.2%
Nov 6, 2025After the close−28.3%
Aug 7, 2025After the close+7.9%
May 8, 2025After the close−9.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TMCIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TMCI
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TMCI

Technical Analysis

TMCI · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 7% below its 20 day and 2% below its 50 day average. It is 21% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 46). The nearest support is the Pivot at $4.30, and the nearest resistance the 50 day average at $4.41.

Short trendBearish
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 10.2%/day
Key levels
$5.4452 week high+26.2%
$4.6020 day average+6.7%
$4.47Swing high (Jun 12)+3.7%
$4.45100 day average+3.2%
$4.44Pivot R1+3.0%
$4.4150 day average+2.3%
$4.31Last close
$4.30Pivot−0.2%
$4.25Swing low (Aug 24)−1.4%
$4.18Pivot S1−3.0%
$3.40200 day average−21.1%
$1.1752 week low−72.9%
Indicators
RSI (14)46.14Middle of its rangeNeutral
MACD0.04Below its signal lineBearish
Stochastic48.4Middle of its rangeNeutral
ADX (14)12.0No clear trend
Williams %R-55.9Oversold below −80, overbought above −20Neutral
CCI (20)-76.8Oversold below −100, overbought above 100Neutral
Rate of change+7.0%Change over 10 sessionsBullish
ATR (14)$0.44Typical daily range, 10.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for TMCI

What happened before

See how TMCI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TMCI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TMCI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TMCIHow many large options trades hit TMCI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TMCI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼41 buying vs 66 selling
  • ●Held by funds +0.1 pts
  • ●Funds holding -1
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding116117−0.9%
In funds' top 10110.0%
Held by funds48.8%48.6%+0.1 pts
New / increased17 / 2431 / 38−40.6%
Reduced / sold out48 / 1832 / 30+6.5%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TMCI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TMCI Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$1.4M5 buys · 1 insider
Sold$00 sales · 0 insiders
2026-05 bought $716K2026-06 bought $389K2026-08 bought $247KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 24John T. TreaceCEOBuy55,944$4.41$247K
Jun 11John T. TreaceCEOBuy52,317$4.03$211K
Jun 1John T. TreaceCEOBuy50,000$3.56$178K
May 28John T. TreaceCEOBuy115,520$2.95$341K
May 14John T. TreaceCEOBuy153,763$2.44$376K
Mar 17, 2025Sean F. ScanlanChief Innovation OfficerSale plan50,000$7.97$399K
Every insider buy and sale for TMCI over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TMCI insider trades →

From SEC Form 4 filings by TMCI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TMCI is in one of them and how their past TMCI trades turned out.

TMCI in the AI portfolios
Loading…

TMCI News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TMCI in an article yet. Here's the latest on the wider market.

TMCI in the news

About Treace Medical Concepts

Treace Medical Concepts is a medical technology company based in Ponte Vedra, Florida. It makes surgical systems, instruments and implants for treating bunions and related midfoot deformities. Its main product line is the Lapiplasty 3D Bunion Correction System, which is supported by options for midfoot correction, minimally invasive osteotomy procedures and great toe fusions. The company sells mainly in the United States to surgeons who treat foot and ankle conditions, including surgical podiatrists and orthopaedic foot and ankle surgeons.

Headquarters
Ponte Vedra, FL